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Abstract 
Batten disease, or juvenile neuronal ceroid-lipofuscinosis, is an autosomal-recessive hereditary disorder that leads to blindness, severe 
neurological degeneration, and premature death. The disease is characterized by massive accumulation of lysosomal storage bodies in 
most tissues. A significant constituent of the storage material is a protein that appears to be almost identical to a small hydrophobic inner 
mitochondrial membrane protein, subunit c of ATP synthase. The protein isolated from the storage bodies contains an e-N-trimethyl-L- 
lysine (TML) residue at amino acid position 43. The presence of TML in the stored protein suggests that one of the lysine residues in 
subunit c is normally trimethylated, and this trimethylation may act as a signal to initiate degradation of the protein. Free TML produced 
by the degradation of TML-containing proteins is the first intermediate in the carnitine biosynthetic pathway. It is possible that 
trimethylated subunit c is a major source of the free TML used in carnitine biosynthesis. If this is the case, one would predict hat the 
genetic defect resulting in the accumulation of TML containing subunit c would also reduce systemic levels of free TML and carnitine. 
To evaluate this possibility, plasma TML and carnitine levels were measured in affected human subjects, heterozygous carriers, and 
normal controls. Both TML and carnitine levels were significantly depressed in the affected individuals. This suggests that subunit c is 
normally a major source of TML for camitine biosynthesis. In Batten disease, failure to degrade the TML-containing form of subunit c is 
probably responsible for the reduction in plasma TML and carnitine levels. 
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1. Introduction 
The childhood neuronal ceroid-lipofuscinoses are a 
group of autosomal-recessively inherited degenerative dis- 
eases that lead to visual loss, seizures, psychomotor and 
cognitive deterioration, and premature death [1-3]. These 
disorders have been classified into three major forms 
(infantile, late-infantile, and juvenile) based on the age of 
onset, clinical course, and genetic analyses. The juvenile 
form, usually referred to as Batten disease, is the most 
common type of ceroid-lipofuscinosis. All three forms are 
characterized by massive accumulation of autofluorescent 
lysosomal storage bodies in most tissues that have been 
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examined. A small hydrophobic inner mitochondrial mem- 
brane protein, subunit c of ATP synthase, has been identi- 
fied as a significant constituent of the storage material in 
the late-infantile and juvenile types [4-7], but does not 
accumulate in the infantile disease [7]. The biochemical 
defects responsible for the lysosomal storage of the subunit 
c protein have not been identified. 
Amino acid composition and sequence analyses of the 
stored protein in Batten disease have revealed that it 
differs in one important aspect from the reported structure 
of normal mitochondrial subunit c. Subunit c isolated from 
normal mitochondrial inner membranes i 75 amino acids 
long and has been reported to contain two lysine residues, 
one at position 7, and the other at position 43 [8,9]. The 
analogous protein isolated from the storage bodies from 
subjects with Batten disease appears to be identical to 
subunit c, except that the amino acid at position 43 is 
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e-N-trimethyl-L-lysine (TML) instead of unmodified lysine 
[10]. The specificity of this modification suggests that 
trimethylation of lysine residue 43 plays a critical role in 
the lysosomal accumulation of this protein. It is probable 
that mitochondrial subunit c is normally trimethylated. 
Since TML does not appear to be present in the protein 
isolated from normal mitochondria, the methylation may 
normally act as a signal to initiate degradation of subunit c. 
A defect in the response to this signal would explain the 
observed accumulation of the TML-containing form of 
subunit c. 
A normal metabolic fate of protein-bound TML is 
conversion to carnitine, an essential cofactor in mitochon- 
drial fatty acid metabolism [11,12]. Apparently TML can 
be synthesized by mammals only by methylation of protein 
lysine residues, and not free lysine [11,13]. Free TML, 
once released from a protein, is converted by the actions of 
four enzymes through a series of three metabolic interme- 
diates to carnitine [14-20]. It is possible that trimethylated 
subunit c is normally a major source of the free TML used 
in carnitine biosynthesis. If this is the case, one would 
predict that the genetic defect resulting in the specific 
accumulation of TML-containing subunit c could also 
reduce systemic levels of free TML and carnitine. To 
evaluate this possibility, plasma TML and carnitine levels 
were measured in individuals with Batten disease, het- 
erozygous carriers, and normal controls. 
2. Materials and methods 
2.1. Human blood samples 
Blood samples were obtained from normal human 
donors, from individuals with definitive diagnoses of juve- 
nile ceroid-lipofuscinosis (Batten disease), and from the 
biological parents of the affected subjects. The diagnoses 
were made on the basis of established clinical and patho- 
logical criteria, which included the presence of characteris- 
tic storage bodies in biopsies [1,2]. Based on the mode of 
inheritance of the disease, the parents are all almost cer- 
tainly heterozygous carriers. Donors were asked to fast for 
2 h prior to having their blood samples collected. Blood 
was drawn from an arm vein into Vacutainer tubes con- 
taining sodium heparin (Becton Dickinson, Rutherford, 
NJ). Samples not collected locally were placed in an 
insulated shipping container with U-Tek refrigerant packs 
(Fisher Scientific) designed to maintain the sample temper- 
atures at approximately 4°C. They were shipped to this 
laboratory via a next-day delivery service. The cellular 
components of the samples were removed by centrifuga- 
tion, and the plasma was collected and frozen in 1-ml 
aliquots at -70°C. Blood samples were collected from 
normal donors between the ages of 5 and 55 years, carriers 
between 26 and 52 years, and affected individuals between 
the ages of 6 and 25 years. 
2.2. Carnitine analyses 
Plasma camitine levels were determined with a ra- 
dioisotope nzymatic assay [21]. In this method, the [14C- 
acetyl]moiety of [acetyl-l-laC]coenzyme A is transferred 
to free carnitine by the catalytic action of pigeon breast 
muscle camitine acetyl-transferase. Unreacted [acetyl-1- 
14C]coenzyme A is separated from the product [acetyl-1- 
14C]camitine by binding the former to an ion-exchange 
resin. The effluent containing labeled acetylcamitine is
assayed in a liquid scintillation spectrometer. Total cami- 
tine was determined by the same method after alkaline 
hydrolysis of the sample to liberate camitine from any 
fatty acylcarnitine esters present. Camitine present as fatty 
acid esters is the difference between total and free cami- 
tine levels. 
2.3. TML analyses 
Plasma TML levels were determined using a modifica- 
tion of the high performance liquid chromatographic 
(HPLC) method described by Lehman and colleagues [22]. 
A one ml plasma aliquot from each donor was spiked with 
25 /zl of a 40 nmol/ml solution of trimethylornithine 
(TMO), which was used as an internal standard. The 
samples were thoroughly mixed and cooled in an ice bath. 
To precipitate the plasma proteins, 260 /zl of ice-cold 2.0 
M perchloric acid was added to each sample with thorough 
mixing. After incubating in an ice bath for 30 min, the 
samples were subjected to centrifugation for 30 min at 
10800×g avg. in a Sorvall RC-5B instrument with a 
swing-out rotor. All centrifugation steps were performed at 
4°C. The resulting supernatants were transferred to 2 ml 
polypropylene vials. The perchloric acid in the samples 
was neutralized by the gradual addition of 260 /zl of 
ice-cold 2.0 M KHCO 3. After standing on ice for 45 min 
with their caps loose to allow the CO 2 evolved to escape, 
the vials were centrifuged at 10800 x g avg. for 15 min. 
The supernatants were transferred to new 2 ml polypropy- 
lene vials and were then acidified by the addition of 50 /zl 
of ice-cold 6 N HC1. After standing on ice for 20 min and 
at room temperature for at least 1 h, the samples were 
evaporated to dryness in a Savant AS160 Speed-Vac. The 
resulting residues were each dissolved in 700 /zl of water. 
The entire plasma extract was applied to an Extra-Sep 
SCX strong cation-exchange column (P.J. Cobert, St. 
Louis, MO) containing 500 mg of resin (H + form) that 
had been washed with 5 ml of water. The entire sample 
was allowed to enter the column, with the eluate being 
discarded. TML and TMO were eluted from the column 
with 0.2 M NHaOH. The first 4.5 ml of the eluate was 
discarded. The following 4.5 ml of the eluate containing 
both the TML and TMO was collected in a polypropylene 
vial and evaporated to dryness in the Speed Vac. The dried 
residues were each dissolved in 400 /xl of water and 
subjected to chromatography on an Extra-Sep SAX strong 
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anion-exchange column (P.J. Cobert) containing 500 mg of 
resin (OH-  form). The columns were supplied in the 
acetate form, and were converted to the OH-  form by 
passing 10 ml of 1.0 M NaOH through each column, 
followed by washing with 50 ml of water. The samples 
that eluted from the SCX columns were applied to the 
SAX columns, and collection of the eluates began immedi- 
ately as the samples were being applied. The columns were 
eluted with 0.1 M NaOH. Collection of the eluates contin- 
ued until a total volume of 4.0 ml had been collected from 
each SAX column. 
The eluates from the SAX columns were evaporated to 
dryness in the Speed Vac, and the resulting residues were 
each dissolved in 50 /xl of water. The amounts of TML 
and TMO in these samples were determined by HPLC 
analysis of their o-phthalaldehyde (OPA) derivatives [22]. 
Twenty microliters of plasma extract was combined with 
an equal volume of a solution consisting of 4.2 mg OPA 
(Pierce Chemical Co. Rockford, IL), 7 ml 125 mM sodium 
borate, pH 10.4, 7 /xl 2-mercaptoethanol, and 140 /xl of 
3% Brij (Pierce Chemical) in ethanol. The OPA reagent 
was made fresh on the day of use. One minute after mixing 
the plasma extract and OPA reagent, 20 /zl of the solution 
was injected onto an Alltech Alltima 5 /zm C-18 column 
(250 mm × 4.6 mm) (Alltech Associates, Deerfield, IL). 
The column was eluted isocratically with a mobile phase 
consisting of 82% acetate buffer (50 mM sodium acetate, 
pH 5.7, 3% tetrahydrofuran) and 18% acetonitrile at a flow 
rate of 1.0 ml/min.  The OPA derivatives of TML and 
TMO were detected quantitatively with a Hewlett-Packard 
1046A fluorescence detector. The detector was set at an 
excitation wavelength of 360 nm with a bandwidth of 25 
nm, and an emission wavelength of 455 nm with a band- 
width of 50 nm. Fluorescence data were collected and 
analyzed with a Hewlett-Packard ChemStation. 
Quantitation was performed by comparing the ratio of 
the TML to TMO peak areas in the chromatograms of the 
samples to that of a calibrated plasma standard. The plasma 
standard was calibrated as follows. A large pool of human 
plasma was collected and divided into 1 ml aliquots, which 
were frozen. A series of aliquots of the plasma pool were 
thawed and spiked with specific amounts of TML, ranging 
from zero to 1500 pmol. Each sample was also spiked with 
1000 pmol of the TMO internal standard. The spiked 
samples were then analyzed as described above, and the 
ratio of the TML to TMO peak areas was calculated for 
each. The value obtained from the aliquot not spiked with 
TML was subtracted from each of the other values, and the 
resulting corrected TML to TMO peak areas were plotted 
as a function of the amounts of TML spiked into the 
samples. This standard curve, which was linear over the 
range of TML concentrations used, was employed to con- 
vert the TML to TMO peak area ratios from the sample 
chromatograms into TML concentrations. 
The samples were extracted and analyzed in batches of 
five or six. With each batch of samples, an aliquot of the 
Table 1 
Effect of Batten disease on plasma carnitine levels among all donors 
examined 
Carnitine (nmol/ml) 
Phenotype n Free Esterified Total 
Normal 40 41.0+8.2 10.9+5.2 51.9+ 12.0 
Carrier 26 36.7+6.1 9.4+2.5 46.1 +6.1 
Affected 14 25.0+7.8 7.9_+2.2 32.9+8.6 
All carnitine values are mean _+ SD. 
calibrated plasma pool was also analyzed. Quantitation of 
TML in each batch of samples was based on a comparison 
with the sample from the calibrated plasma pool that was 
analyzed at the same time. 
2.4. Statistical analyses 
The data were subjected to analysis of variance 
(ANOVA) to determine whether plasma carnitine or TML 
levels were related to genetic status relative to Batten 
disease. Comparisons among the individual groups (nor- 
mal, carrier, and affected) were performed using the Stu- 
dent-Newman-Keuls test [23]. Regression analysis was 
performed to assess potential relationships between the 
ages of the donors and plasma carnitine and TML levels. 
3. Results 
3.1. Plasma carnitine levels 
The mean total plasma carnitine concentration i sub- 
jects with Batten disease was only 63% of the level 
observed in normal control donors (P  < 0.005) (Table 1). 
This reduction was due primarily to lower free carnitine 
concentrations (Table 1). The mean concentration of free 
carnitine in the affected individuals was 61% of that in 
normal donors (P  < 0.005), whereas the mean camitine 
ester level in the affected donors was not significantly 
different from that in the normal subjects (Table 1). Plasma 
carnitine concentrations in the carders were intermediate 
between those of the normal and affected subjects (Table 
1). The mean total carnitine concentration i the carriers 
was 89% of that observed in the normal group (P  < 0.03). 
This reduction was due primarily to a lower mean plasma 
Table 2 
Effect of Batten disease on plasma carnitine l vels among male donors 
Carnitine (nmol/ml) 
Phenotype n Free Esterified Total 
Normal 19 45.1 +7.8 10.9+6.1 56.0+ 10.9 
Carrier 13 37.7+5.7 8.9+1.8 46.6+5.7 
Affected 7 27.6+7.9 7.9+1.3 35.5+7.6 
All carnitine values are mean +__ SD. 
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Table 3 
Effect of Batten disease on plasma carnitine levels among female donors 
Carnitine (nmol/ml) 
Phenotype n Free Esterified Total 
Normal 21 37.3+7.3 10.9+5.9 48.2±10.9 
Carrier 13 33.8+9.0 9.5+2.5 43.3±8.2 
Affected 7 22.5+7.1 7.9+3.1 30.4__+8.7 
All carnitine values are mean-+-SD. 
free camitine concentration i  the carriers, which was 90% 
of the control value (P < 0.05). 
Females typically have slightly lower mean plasma 
carnitine levels than males. Although approximately equal 
numbers of males and females were utilized in each group, 
the carnitine data were analyzed individually for each sex 
to evaluate the possibility that the effect of the disease on 
carnitine levels was sex specific. The results of these 
analyses are presented in Tables 2 and 3. When the data 
from each sex were evaluated separately, the relative ef- 
fects of Batten disease on total and free carnitine concen- 
trations were found to be almost the same in males and 
females. In both cases, mean total plasma carnitine concen- 
trations were approximately 37% lower in affected individ- 
uals than in normal subjects (P < 0.005 for both males and 
females). Again, this was due primarily to a reduction in 
the levels of free carnitine. Mean total carnitine levels in 
male and female carriers were 83 and 90% of normal 
respectively. 
It has been reported that plasma camitine levels do not 
change as a function of age in normal healthy humans [24]. 
The present analyses confirmed this in the normal and 
carrier donors. Linear regression analysis of the carnitine 
concentrations a a function of age in these two groups 
indicated that there was no significant correlation between 
plasma carnitine concentration a d age over the age spans 
that were examined. It is possible that the decreases in 
plasma carnitine levels in the affected individuals were 
secondary to the disease pathology. If this was the case, 
one would expect plasma carnitine levels to progressively 
decrease with increasing age in the affected subjects. This 
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Fig. 1. Total plasma carnitine concentrations in female (O)  and male (O) 
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Fig. 2. Plasma trimethyllysine (TML) concentrations in healthy subjects, 
in the parents of children with Batten disease (carriers). and in affected 
children. Values shown are mean___ SE. 
was not found to be the case (Fig. 1). The lowest plasma 
carnitine concentration was actually found in the youngest 
donor, and most affected donors had plasma camitine 
concentrations in the range of 25-40 nmol/ml (Fig. 1). 
Regression analysis indicated that there was no significant 
correlation between plasma carnitine concentration a d age 
in the affected subjects. 
3.2. Plasma TML concentrations 
The mean plasma TML concentration i the normal 
donors was 651 pmol/ml (Fig. 2). This was fairly close to 
the value for normal human subjects reported by Lehman 
and colleagues [22]. Carriers had a 20% lower mean 
plasma TML concentration (523 pmol/ml), but this was 
not significantly different from the normal controls. In 
affected individuals, on the other hand, the mean plasma 
TML concentration was only 333 pmol per ml. This was 
only 51% of the normal concentration. Chromatograms 
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Fig. 3. Chromatograms of the OPA derivatives of TML from plasma 
samples (peaks labeled 2) and the TMO internal standard (peaks labeled 
1). (A) Preparation from a normal donor. (B) Preparation from a donor 
with juvenile ceroid-lipofuscinosis. Fluorescence is in arbitrary units 
representing the fluorescence detector response amplitude. 
196 M.L. Katz / Biochimica et Biophysica Acta 1317 (1996) 192-198 
-~" 450 E 
a. 400 
o 
E 
o .  
. j  350 
300 
a- 
250 
O 
o 
0 • 
•o  
O 
O 
I t I I I 
5 10 15 20 25 
Age (years) 
Fig. 4. Plasma TML concentrations in female (0 )  and male (O)  subjects 
with juvenile ceroid-lipofuscinosis. 
--'=- 1200 
E 
ca. 1000 
o 
800 
F-  
m 600 
o- 400 
0 • 
o 
o 
o • 
o 3 ° 
~ • o ° 
O 
I I I I I 
10 20 30 40 50 
Age (years) 
Fig. 5. Plasma TML concentrations in normal female (Q)  and male (O)  
subjects. 
illustrating typical HPLC analyses for TML in samples 
from a normal and an affected onor are shown in Fig. 3. 
The reduction in TML concentration i the affected sub- 
jects relative to the levels in both the normal and cartier 
individuals was statistically significant (P  < 0.005 for both 
comparisons). As with the carnitine levels, the reduction in 
plasma TML concentration was most pronounced in the 
youngest affected onors examined (Fig. 4). Among nor- 
mal donors, there was a trend toward lower plasma TML 
concentration with increasing age for donors between 9 
and 50 years old (Fig. 5). Thus, if plasma TML concentra- 
tions in the affected onors are compared only to those of 
normal subjects in the same age range (6 to 25 years), the 
disease-related decrease in TML concentration is 55% 
(P < 0.005). 
4. D iscuss ion  
Batten disease is characterized by lysosomal storage of 
the subunit c protein of mitochondrial ATP synthase [5-7]. 
The same protein is stored in a number of putative animal 
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Fig. 6. Carnitine biosynthetic pathway (adapted from Rebouche, [20]). Specific lysine residues of specific proteins (apparently including subunit c) are 
enzymatically trimethylated. The free TML formed upon degradation of the protein is then converted to carnitine through the indicated enzyme-catalyzed 
steps, 
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models for this disease [6,25-28]. Why specific lysosomal 
accumulation of this protein occurs is not yet known. 
Subunit c is derived by specific proteolytic leavage from 
either of two larger precursor proteins [29]. These precur- 
sor proteins are encoded by separate nuclear genes [29]. 
The precursors differ only in their N-terminal regions that 
direct import of the protein into mitochondria [29]. These 
N-terminal regions are removed upon mitochondrial up- 
take so that a single form of the protein is incorporated 
into mitochondria. Only the mature protein, not either of 
the precursor forms, accumulates in Batten disease. Studies 
by Medd and colleagues have indicated that the subunit c 
genes are not over-expressed in a sheep model for Batten 
disease [30]. In the late-infantile form of the disease, 
subunit c accumulation is not accompanied by any changes 
in the rates of transcription of the subunit c gene, or in the 
rates of subunit c protein synthesis [31]. Thus, it is likely 
that the defect responsible for subunit c storage occurs at a 
stage in the life cycle of the protein after its import into the 
mitochondria. Accumulation of subunit c apparently occurs 
because of a defect in the degradative pathway for this 
protein. 
Little is known about the mechanisms of mitochondrial 
protein turnover. However, it has been shown that the 
half-lives of individual mitochondrial proteins differ sub- 
stantially [32]. The latter observation is consistent with the 
possibility that subunit c is normally degraded by a unique 
pathway. Analyses carried out in this laboratory led to the 
discovery that the stored form of subunit c in humans and 
animals differs at one amino acid residue from the form 
isolated from normal mitochondria [8-10,27,33]. The pro- 
tein stored in Batten disease contains TML at residue 43 
instead of unmodified lysine. The correlation between the 
presence of this post-translational modification and the 
lysosomal storage of the protein suggests that methylation 
of lysine residue 43 may play a key role in the accumula- 
tion of subunit c. Because of the specificity of this modifi- 
cation, it is likely that it occurs normally. The fact that the 
methylated form of the protein was not observed in mito- 
chondria from normal humans or animals suggests that the 
methylation may act as a signal to initiate degradation of 
subunit c. Thus, in normal individuals the methylated form 
would not be present in appreciable amounts. A failure to 
initiate degradation of subunit c in response to the meth- 
ylation of lysine 43 could account for the accumulation of
this protein in Batten disease. 
Trimethylation of protein lysine residues is mediated by 
a group of protein methyl transferase nzymes that cat- 
alyze the transfer of methyl groups from S-adeno- 
sylmethionine to the e-amino group of specific lysine 
residues of specific protein substrates [34,35]. Apparently 
no analogous enzyme exists in mammals to catalyze the 
methylation of free lysine. Thus, TML can only be synthe- 
sized by methylation of protein lysine residues. When 
these proteins are degraded, free TML is released. This 
amino acid is converted through the sequential actions of 
four enzymes into carnitine (Fig. 6) [20]. In normal indi- 
viduals, it appears that a fraction of the carnitine require- 
ment is satisfied by dietary intake, and the remainder is 
supplied by metabolism of TML [36]. A number of pro- 
teins, such as myosin and histones, have been identified 
that contain TML residues [37,38]. These proteins proba- 
bly all contribute to carnitine biosynthesis to varying de- 
grees. Because of its abundance and ubiquitous distribution 
relative to other TML-containing proteins, subunit c could 
serve as a major source of TML for carnitine biosynthesis. 
If this is the case, one would predict that a defect in the 
degradation of TML-containing subunit c would result in 
depressed levels of both TML and carnitine. The data 
obtained in this study indicate that the accumulation of 
TML-containing subunit c in Batten disease is accompa- 
nied by significant decreases in plasma camitine and TML 
levels. Thus, it appears likely that the defect in this disease 
results in a specific impairment in the degradation of the 
subunit c protein after it has been trimethylated at lysine 
residue 43, and that subunit c is probably a major source of 
TML for carnitine biosynthesis n normal individuals. 
The observed ecreases in plasma carnitine and TML 
concentrations donot appear to be secondary to the disease 
pathology. The concentrations of both compounds were 
significantly depressed in the early stages of the disease 
before pathological changes had become pronounced. In, 
addition, heterozygous carriers, who show no overt disease 
pathology, had moderately reduced plasma carnitine and 
TML concentrations. These observations indicate that the 
reductions in the levels of these two compounds i proba- 
bly directly related to the genetic defect responsible for 
Batten disease. 
A dog model for Batten disease was first established by 
Koppang over 30 years ago [39]. As in human Batten 
disease, affected dogs accumulate massive amounts of 
TML-containing subunit c protein in a variety of tissues 
[27]. Also as in humans, the accumulation of this modified 
protein is accompanied by depressed plasma carnitine and 
TML levels [40]. Based on these biochemical similarities, 
the dog model should be useful in testing the hypothesis 
that the primary defect in Batten disease involves an 
impairment in the degradation of TML-containing subunit 
C. 
Although plasma carnitine levels in subjects with Batten 
disease were significantly lower than normal, they were 
not depressed to the degree that one would expect the 
affected individuals to display the symptoms of carnitine 
deficiency. Typical symptoms of carnitine deficiency in- 
clude progressive cardiomyopathy, muscle weakness, and 
hypoglycemia sometimes leading to permanent brain dam- 
age [41]. Individuals with these symptoms usually have 
plasma carnitine levels of 10 nmol per ml or less [41,42]. 
Thus, the pathology in Batten disease is more likely to be 
directly related to accumulation of methylated subunit c 
rather than to the resultant depression of tissue carnitine 
levels. 
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In summary, the data suggest that after its incorporation 
into mitochondria, subunit c is at some point enzymatically 
trimethylated at lysine residue 43. In normal individuals, 
this methylation probably targets the protein for proteolytic 
degradation. Upon degradation, free TML is released. The 
TML is then metabolized to form carnitine. A defect in 
recognition of the methylation signal would account for 
the observed accumulation of the trimethylated form of 
subunit c, and for the depressed levels of circulating TML 
and carnitine. If the above hypothesis correct, TML-con- 
taining subunit c is probably a major source of TML for 
carnifine biosynthesis n normal individuals. 
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